The board of the directors of The United Laboratories International Holdings Limited announced that, based on the unaudited consolidated management accounts of the company for the six months ended 30 June 2016 prepared in accordance with Hong Kong Financial Reporting Standards, the Group's unaudited interim results for the six months ended 30 June 2016 is expected to record a slight loss, while the net profit for the six months ended 30 June 2015 is approximately HKD 280,300,000. Turing from profit into loss is mainly due to decreases in sales volume and selling prices of the major intermediate product 6-APA and major bulk medicine product Amoxicillin during the period. Decrease in production lead to higher production costs and resulting significant decline in gross profit.